April 2026 Research Update

Studies this month added real-world and early signals about treatments that target mTOR (a key overactive pathway in TSC), plus a few other approaches studied in very small groups. In routine care, starting an mTOR inhibitor was linked to fewer kidney angiomyolipoma bleeding events and fewer embolization procedures, while a separate pediatric epilepsy study reported higher seizure-response rates in children who received sirolimus or everolimus as add-on treatment. Alongside this, several small reports explored surgery or device-like approaches for seizures or brain tumors, and these results were more mixed and harder to generalize because numbers were small. [1] [2] [3] [4]

For kidney angiomyolipomas (benign kidney tumors that can bleed), a multicenter French cohort compared periods before and after people started mTOR inhibitors (mostly everolimus). After mTOR inhibitor initiation, the study reported a lower rate of angiomyolipoma-related hemorrhage and a lower rate of selective arterial embolization sessions. The same report also noted that many patients with higher-risk imaging features and complications still had not started an mTOR inhibitor in routine care, highlighting a gap between risk and treatment use in the real world. [1]

For epilepsy in children with TSC, a retrospective comparison of those who did versus did not receive add-on mTOR inhibitors (sirolimus or everolimus) found higher seizure-response rates in the treated group, using a threshold of at least 50% seizure reduction. About half of treated children had side effects, and severe side effects were reported as uncommon, with sirolimus and everolimus described as having comparable safety in this dataset. Because the study was not randomized, it cannot prove the medicines caused the difference, but it adds to the picture that mTOR inhibitors may be linked with better seizure control for some children in routine practice. [2]

For surgical and procedure-based seizure or tumor care, results varied by condition and were often based on small numbers. In a tiny infant series using MRI-guided laser therapy (LITT) for drug-resistant epilepsy, seizure freedom at 12 months occurred in children with focal cortical dysplasia, while the two infants with TSC still had seizures (though one improved after later surgery), and no procedure-related complications were reported. For SEGA (a brain tumor that can block fluid flow), a larger pediatric surgical series reported good tumor control with no permanent morbidity, with worse outcomes linked to preoperative hydrocephalus and higher recurrence risk linked to tumors on both sides. [3] [4]

This month strengthens the idea that mTOR inhibitors are being used across different TSC problems, and that in routine care they are linked with fewer kidney angiomyolipoma bleeding events and, in a separate pediatric dataset, with higher chances of meaningful seizure reduction. These findings may matter now because they describe what happened to people receiving treatments already used in TSC, but they are still limited by the fact that the epilepsy study and the kidney study were observational rather than randomized comparisons. For surgery and procedure-based approaches, the newer or smaller reports help clarify what is feasible and what outcomes were seen in specific settings, but they are not enough to predict results for most patients with TSC. [1] [2] [3] [4]

Several studies this month focused on how TSC is identified and how differences in genes and brain findings relate to seizures and learning or behavior differences. Across these studies, genetics repeatedly showed up as useful not only for confirming TSC (TSC1/TSC2 variants), but also for explaining why two people with TSC can have different risks for epilepsy and TAND (TSC-associated neuropsychiatric differences). Imaging studies added that some brain and eye changes can be detected or characterized more precisely with specialized scans, including in areas that look normal on standard imaging. [5] [6] [7] [8] [9]

In children with TSC, one study found that genetic testing identified TSC1 or TSC2 variants in most patients and expanded the list of known variants by reporting new ones. It also described how often seizures were the first sign and how common other features were in that group, reinforcing that epilepsy is often an early and central part of pediatric TSC. This type of work mainly adds to understanding of diagnosis and the range of genetic findings, rather than changing day-to-day management on its own. [5]

Looking beyond TSC1 and TSC2, a larger sequencing study reported that a small proportion of people with TSC also had additional disease-causing genetic changes in other epilepsy or neurodevelopment-related genes. In practical terms, this suggests that for a minority of families, genetics may help explain why epilepsy or developmental differences seem more severe or different than expected, because more than one genetic factor may be present. The authors also noted that many participants had potential "targeted therapy" implications, but the summary did not specify which therapies applied to which individuals. [6]

For TAND severity (a broad term covering learning, behavior, mental health, and related differences in TSC), a registry study reported higher TAND scores in people with active epilepsy and in those with TSC2 variants compared with seizure-free patients or those with TSC1 variants. The same study found an interaction between genotype and seizure status, meaning the combination of gene type and seizure activity related to score differences. This does not mean genes or seizures "cause" TAND on their own, but it helps clarify which groups may carry higher measured burden in this dataset. [7]

Specialized imaging work added detail on what TSC looks like in the eye and the brain. In pediatric eye imaging, OCT (a detailed retina scan) detected additional retinal astrocytic hamartomas that were not seen on standard eye exam photos, especially smaller lesions. In brain imaging, MR spectroscopy (a scan that estimates brain chemicals) showed differences in several metabolite ratios not only in tubers but also in brain regions that appeared normal, suggesting there can be "hidden" changes beyond visible lesions. [8] [9]

This month adds clarity that genetics and specialized imaging can sometimes explain more of the TSC story than standard testing alone, especially for epilepsy, development, and eye findings. For many families, this matters mainly by improving understanding of why symptoms differ from person to person and by supporting more personalized risk discussions, rather than pointing to a single new treatment. Important uncertainties remain, including how often additional non-TSC genetic findings change long-term outcomes, and how specialized brain chemical scans should be used outside of research settings. [5] [6] [7] [8] [9]

The reports this month included tumors and other clinical findings relevant to TSC or its molecular pathways, although not every patient described in these case reports was diagnosed with TSC. Taken together, these cases do not tell us how common these situations are, but they help document unusual complications, diagnostic confusion (one condition looking like another), and how care teams approached complex decisions. Many of the reported situations involved tumors related to the same mTOR pathway that drives TSC, which is why mTOR inhibitors appeared in several of these narratives. [10] [11]

Several reports centered on kidney or kidney-area masses, where imaging and pathology were important for sorting out what the mass was. One patient with TSC and diabetes had a giant renal angiomyolipoma with hemorrhage and end-stage kidney failure, and genetic testing identified both a TSC2 variant and an HNF1B variant. Another report, in a 54-year-old woman not described as having TSC, described a large mass first suspected to be a liposarcoma that turned out to be a benign fat-predominant angiomyolipoma after surgery, showing how these lesions can mimic other tumors on imaging. [10] [12]

Two reports focused on PEComas (a family of rare tumors that can be linked to TSC). In an 18-year-old with TSC, a renal mass thought to be angiomyolipoma was found to be a malignant renal PEComa after surgery, with planned mTOR inhibitor therapy and close imaging follow-up. In a separate adult case, a woman not described as having TSC had an unresectable liver PEComa with TSC2 alterations in the tumor; prolonged nab-sirolimus (an albumin-bound form of sirolimus) was associated with modest tumor shrinkage and long-lasting stability that allowed liver transplant listing and transplantation. [11] [13]

A few case reports described less common but important complications outside of tumors. One infant with TSC developed a large abdominal aortic aneurysm and underwent open repair with a graft, followed by an early clot in the graft that required urgent revision and then recovery. Another adolescent with TSC developed primary antiphospholipid syndrome presenting with an eye-artery thrombosis and vision loss, with lupus anticoagulant positivity and a confirmed TSC1 variant. [14] [15]

One report described a minimally invasive approach to removing a large intraventricular SEGA in a child with TSC, with a staged surgery plan and additional therapies, and an estimated 90% to 95% removal along with symptom improvement. As with other single cases, this mainly shows what was possible in one center and does not predict typical outcomes. [16]

These single-patient stories matter most as awareness-building rather than as evidence that a certain approach will work for most people. They help clarify that TSC can overlap with other genetic findings, that kidney-area masses may require careful diagnosis to distinguish angiomyolipoma from rarer PEComas, and that vascular or clotting problems can occur in individual patients. What remains uncertain is how often these rare events happen in the wider TSC community and which patients, if any, should expect similar courses, because case reports cannot answer frequency or predictability. [10] [11] [14] [15] [16]

Early-stage research this month explored new drug targets and biological pathways that may contribute to seizures or tumor-like growth in TSC-related models, but these are not tests of treatments in people. Across these studies, mTOR signaling kept appearing as a central hub, and researchers explored whether combining mTOR inhibitors with other approaches could strengthen effects in cells or animals. These results are best viewed as "what might be worth testing next," not as evidence that a new therapy is ready. [17] [18] [19]

One mouse and cell study tested GSK-J4 in Tsc1/2-deficient models and reported reduced tumor-like features, with more cell-cycle arrest and cell death, and it also reported better results when GSK-J4 was combined with rapamycin. In Tsc1- or Tsc2-deficient mice, the combination was reported to reduce kidney impairment compared with what was seen in the disease model. This supports the idea that combination strategies might be explored when mTORC1 inhibitors alone are not enough, but it remains animal research. [17]

A separate experimental study related to LAM (a lung disease linked to TSC changes) reported higher IL-6 levels in patient samples and showed that estrogen and IL-6 signaling together increased aggressive behaviors in TSC2-deficient cells in the lab. Inhibiting both the estrogen receptor (ERalpha) and STAT3 pathways together reduced cell growth and movement in those experiments. This work points to IL-6/STAT3 as a possible future target to study, but it does not demonstrate patient benefit. [18]

Two studies focused on seizures in animal models and on molecular changes seen in brain tissue. In a TSC mouse model, simufilam reduced worsening of EEG-measured seizures in a dose-related way, with higher drug levels linked to fewer daily seizures late in monitoring. In a rat model of focal cortical dysplasia (with comparisons to human TSC tissue findings), rapamycin and ceftriaxone were reported to influence alpha-synuclein-related changes and seizure activity, connecting seizure biology to mTOR and a glutamate transporter pathway. [20] [19]

One qualitative study explored a different kind of early research: whether young adults with TSC would find smartphone-based check-ins (Smart EMA) acceptable for tracking daily experiences and mental health communication. Participants described potential benefits if the tool is personalized and easy to use, and they also raised barriers such as unpredictability and varying abilities. This is not a clinical outcome study, but it helps define what a useful future monitoring tool would need to look like in real life. [21]

This set of studies mainly matters for the future, because it maps possible next steps for new treatments or better ways to track day-to-day health in TSC. It helps clarify which biological pathways researchers are focusing on right now, including mTOR-related combination strategies, inflammation and hormone signaling in LAM, and seizure-related brain pathways in animal models. What remains uncertain is whether any of these approaches will be safe and effective in people with TSC, since the work was done in the lab, in animals, or as interviews rather than in clinical trials with patient outcomes. [17] [18] [20] [19] [21]

One study this month described how often different brain-related TSC features were recorded in a specific region over time, showing how TSC can look different depending on who is captured in local healthcare records. It reported the frequencies of epilepsy, cortical tubers, SEGA, and cognitive or behavioral features, alongside which TSC1 or TSC2 variants were found and how often targeted therapy was used. This kind of study does not test a treatment, but it helps document what is being recognized and recorded in routine care in that setting. [22]

In the Republic of Bashkortostan dataset, the authors reported a regional prevalence estimate and noted that some recorded feature rates were lower than international meta-analyses. They also stated that there were no data available on some behavioral diagnoses in the records they reviewed, which may affect comparisons. The report included that a small number of patients had received targeted therapy, but the summary did not provide outcomes linked to that treatment use. [22]

This study matters mainly as context: it helps clarify what TSC features are being documented in one healthcare system and how often genetic variants are being identified. For patients, it is a reminder that reported rates can depend on access to testing and what is recorded in medical charts, and that missing information (like certain behavioral conditions) can make a region look different from others. It does not directly change care, but it can support planning for what kinds of services and evaluations may be needed in a community. [22]